摘要
目的探讨C-erbB-2在乳腺癌中的表达意义。方法采用免疫组化SP法检测161例乳腺浸润性导管癌中C-erbB-2的表达。结果C-erbB-2在<50岁与≥50岁年龄组表达率分别为27.43%和31.25%,差异无统计学意义(P>0.05);在浸润性导管癌Ⅰ、Ⅱ、Ⅲ级中表达率分别为19.05%、24.21%、42.22%,在Ⅰ、Ⅱ级中明显低于Ⅲ级中(P<0.05);在淋巴结无转移组、低转移组表达率分别为20.43%、29.41%,明显低于高转移组44.0%(P<0.05)。结论C-erbB-2的表达与乳腺癌的组织学分级高,淋巴结高转移率密切相关。C-erbB-2的检测可作为乳腺癌预后判断的重要参考指标。
Objective To investigate the significance of expression of C- erbB-2 in breast carcinoma. Methods The expression of C-erbB-2 was detected by S-P immunohistochemical technique in 161 cases of breast invasive ductal carcinoma. Results The expressing rates of C-erbB-2 were 27.43% and 31.25% in the age group above 50 and below 50 years respectively, and there was no significant difference between the two age groups（ P 〉0.05）. The positive expressing rates of C-erbB-2 were 19.05% , 24.21% and 42.22% in breast carcinoma tissues at grade 1,2 and 3 respectively, which was higher in grade 3 than that in other two groups （ P 〈 O. 05 ）. C-erbB-2 expressing rates in patients without and with low frequency of lymph node metastases were 20.43%, 29.41% respectively, which was significantly higher than that （ 44. 0% ） in high frequency of lymph node metastases （ P 〈 0.05 ）. Conclusion The over-expression of C-erbB-2 was closely related with a high histological grade and high frequency of lymph node metastases. C-erbB-2 may be a valuable prognostic indicator for breast invasive ductal carcinoma.
出处
《河北医药》
CAS
2009年第11期1307-1308,共2页
Hebei Medical Journal
